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Abstract
Background: Hypertension is a pathological increase in blood pressure that affects
nearly 30% of the U.S. population and is a primary modifiable risk factor for
cardiovascular disease. Despite advancements in prevention and treatment,
hypertension is still one of the most common conditions around the world, and for a
majority of cases the causal mechanisms remain to be fully elucidated. A growing body
of literature suggests that oxidative stress status may play an etiological role in many
chronic conditions, including hypertension. Specifically, a systemic overabundance of
reactive oxygen species may give rise to endothelial dysfunction, increased sodium and
H2O retention, and alterations in sympathetic outflow, leading to an increase in blood
pressure.
Purpose: The main objective of this study is to investigate the prospective association
between F2‐isoprostanes, a validated biomarker of oxidative status, and development of
hypertension in a large, multi‐centered, multi‐ethnic cohort of adults aged 40‐69 at
baseline.
Methods: This is a secondary data analysis that utilized previously collected data from
the Insulin Resistance Atherosclerosis Study. 844 participants were included in the
analysis. Briefly, four urinary F2‐isoprostane isomers (F2‐IsoP1, F2‐IsoP2, F2‐IsoP3, and
F2‐IsoP4) were quantified using liquid chromatography/ tandem mass spectrometry and
adjusted for urinary creatinine levels. Hypertension was assessed at baseline and
follow‐up visits and defined as systolic blood pressure > 140 mm Hg and/or diastolic
blood pressure > 90 mm Hg and/or currently taking antihypertensive medications.
Crude associations between study population characteristics and hypertensive
status were analyzed with the chi‐square and Wilcoxon‐rank sum tests. Crude
associations between study population characteristics and F2‐isoprostane levels were
analyzed with Wilcoxon‐rank sum, Kruskal‐Wallis, and Spearman’s rank correlation
measures. Finally, the adjusted prospective associations between hypertensive status
and F2‐isoprostane concentrations were modeled using logistic regression.
Results: Of the 844 participants who were included in the study, 258 (31%) were
classified as hypertensive at baseline. Among the 586 participants who were
normotensive at baseline, 123 (21%) developed hypertension over the five‐year study
period. Importantly, none of four F2‐isoprostane isomers predicted a significant
increase in the odds of developing hypertension, as indicated by their odds ratio 95%
confidence intervals; F2‐IsoP1: (0.85, 1.31), F2‐IsoP2: (0.62, 1.13), F2‐IsoP3: (0.80, 1.27),
and F2‐IsoP4: (0.84, 1.29).
Conclusion: Previous studies have investigated the association between oxidative
status and hypertension prevalence, however the cross sectional nature of the study
designs have made it difficult to establish temporality between exposure and outcome.
To our knowledge, this is the first study to model the odds of developing hypertension
as a function of F2‐isoprostane levels. The results of this study suggest that oxidative
status is not involved in the development of hypertension.
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Chapter I
Introduction
1.1 Background
Hypertension, a pathological condition of the cardiovascular system, affects one
out of every three adults in the United States and its prevalence is expected to increase
7.2% by year 2030 (1). Hypertension is also a primary antecedent of cardiovascular
disease, which is ranked first in the cause of death worldwide (2). When an elevated
blood pressure persists and cannot be attributed to a specific cause, such as renal
disease, it is diagnosed as essential or primary hypertension (3). Essential hypertension
affects a majority of hypertensive cases and a complete understanding of its etiology
remains unknown (4). There is increasing evidence that suggests oxidative stress plays a
causal role in the pathogenesis of many chronic diseases, including hypertension (5).
Importantly, hypertension is a modifiable risk factor. Thus, if a relationship between
oxidative stress and hypertension were established, this would provide a foundation for
prevention.

1.2 Purpose of Study
The primary objective of this study is to assess the adjusted prospective
association between F2‐isoprostanes, a biomarker of oxidative status, and development
of hypertension in a large cohort. Crude associations between F2‐isoprostanes, a set of
demographic and anthropometric variables, and hypertensive status will also be
assessed in order to identify potential confounding relationships.
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Chapter 2
Literature Review
2.1 Hypertension
Hypertension is a chronic disease of the cardiovascular system characterized by a
pathologic elevation of arterial blood pressure (6). Left uncontrolled, hypertension can
promote damage to various organs and increase the risk of cardiovascular events
including stroke, aneurysm, and ischemia (3). Blood pressure is a function of cardiac
output and peripheral resistance, and it is believed that alterations in peripheral
resistance contribute substantially to a hypertensive state (4). Hypertension is
commonly diagnosed by averaging respectively several systolic (SBP) and diastolic blood
pressure (DBP) measurements taken on different occasions (3). The Seventh Report of
the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of
High Blood Pressure defines hypertension as a DBP ≥ 90 mm Hg or SBP ≥ 140 mm Hg
(7). The majority of hypertensive cases are classified as idiopathic or essential
hypertension, in which there is no clinically identifiable cause (6). In addition,
hypertension does not display any outward signs, thus it is commonly referred to as “the
silent killer”(8).

2.2 Epidemiology of Hypertension
Hypertension is one of the most commonly diagnosed conditions in the
world (9). In the U.S. alone, it affects approximately 1/3 of the population (10). In the
past decade, the U.S. has experienced a 41.5% increase in the number of deaths due to
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hypertension. Many treatments have been designed to regulate blood pressure;
however, only 46% of hypertensive individuals have this condition under control (1). It
is estimated that 83% of individuals with untreated hypertensive will die of ischemic
heart disease or stroke (11). Hypertension also consumes valuable resources. In 2010,
essential hypertension was involved in over 43 million medical care visits. In the same
year, the health care cost of hypertension was an estimated $46 billion, and projections
suggest an increase to $274 billion by 2030 (1). Despite the efforts of several national
initiatives to improve hypertension prevention, detection, and treatment, there is an
urgent need for continued research in the pathogenesis of hypertension and its deadly
sequelae.

2.3 Risk Factors for Hypertension
Hypertension is believed to be a multifactorial condition influenced by genetics,
environment, and behaviors (12, 13). In fact, researchers estimate that 30%‐60% of
blood pressure variability can be explained by genetics (14). The distribution of
hypertension in the population is influenced by many characteristics including age, race,
geographic location, gender, and socio‐economic status (3). Lifestyle choices such as
alcohol intake (15) and poor diet (16) have also been linked to hypertension.
Hypertension prevalence is disproportionately high in the southeastern United States
(17). Some reasons for this include a greater proportion of African Americans,
decreased physical activity, and increased sodium intake.
Hypertension is often associated with a cluster of metabolically related
conditions, namely dyslipidemia, glucose intolerance, and abdominal obesity (18, 19).
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Data from the Framingham Heart Study suggests that with respect to each of these
conditions, hypertension occurs independently of the other three about 20% of the time
(20). It is believed that elevated levels of reactive oxygen species (ROS) mediate the
relationship between obesity, insulin resistance, and hypertension (21). Experimental
evidence suggests that a pathologic change in the renin angiotensin system, which is
responsible for blood pressure regulation, is closely linked to obesity (22, 23). It has also
been hypothesized that decreased physical activity and over‐nutrition is responsible for
free fatty acid and glucose overload in cells, which results in pathologic imbalances in
ROS levels (24).

2.4 Reactive Oxygen Species and Oxidative Stress
ROS are a group of highly reactive molecules containing oxygen and found in all
aerobic organisms (25). ROS are constantly produced by normal cellular processes and
are involved with many functions including pathogen defense, signaling pathways, and
elicitation of mitogenic responses (26).
Within the cardiovascular system, ROS such as superoxide and hydrogen
peroxide play an important role in endothelial function, vascular tone, and cardiac
function (27). Redox signaling pathways, which rely on temporary imbalances between
pro‐oxidant and antioxidant molecules, modulate production of nitric oxide (NO), which
in turn controls vascular tone (28, 29). Within the vasculature, cytokines and hormones
such as angiotensin‐II, endothelin‐I, and urotensin‐II stimulate the production of
superoxide and other ROS via NADPH oxidase activation (30). Because ROS play an
integral role in cellular functions involved with blood pressure regulation, researchers
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have hypothesized that significant and sustained disturbances in the reduction‐oxygen
(redox) balance drive the pathology of hypertension and other cardiovascular
pathologies (31).
Redox signaling relies on a temporary imbalance between pro‐oxidant and
antioxidant molecules (25). In fact, evolution has equipped all aerobic organisms with
an elaborate antioxidant defense system to maintain a steady state redox balance. By
scavenging free radicals, enzymatic antioxidants such as superoxide dismutase and
glutathione peroxidase protect cellular components against oxidative damage (27).
However, prolonged increases in ROS and/or decreases in antioxidant capacity may
cause cellular damage or interrupt normal cellular functioning.
Oxidative stress occurs when there is a significant imbalance between ROS
production and antioxidant defense within the cells and tissues (32). In contrast to the
temporary fluctuations in redox balance that drives cellular signaling, a systemic and
chronic overabundance of ROS can react with essential biological molecules, changing
their structure and function. Cellular components such as proteins, DNA, and lipids are
frequent targets of ROS attack (31).
Several lines of evidence connect the over‐stimulation of ROS generating
enzymes and subsequent increases in ROS levels to hypertensive alterations in the
cardiovascular system. Certain genetic, hormonal, and hemodynamic factors are
believed to be responsible for the over‐activation of NADPH oxidase, resulting in
excessive production of ROS including superoxide, hydrogen peroxide, and peroxynitrite
(32). An overabundance of these reactive species is believed to decrease NO
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bioavailability within vascular tissue, leading to endothelial dysfunction, reduced
vasodilation, and increased vasoconstriction (28, 33). Specifically, superoxide
production may inhibit prostacyclin formation and accelerate breakdown of nitric oxide,
an inhibitor of platelet aggregation (34). Angiotensin‐II, a potent vasoconstrictor,
directly influences blood pressure and is known to stimulate superoxide production (35,
36). Oxidative stress has also been shown to indirectly promote platelet activation, cell
adhesion, and inflammatory responses within blood vessels by disrupting the
thromboxane receptor interaction with its ligand TxA2 (37). Importantly, endothelial
dysfunction and inflammation may perpetuate additional ROS production, thus
establishing a feedback cycle between the initial factors and the hypertensive state (29).
Pathogenic increases in oxidative molecules may also occur in other tissues
responsible for blood pressure regulation. An over‐activation of ROS‐generating
enzymes have been implicated in the alteration of redox signaling in kidney cells, which
may promote glomerular damage and increased sodium and H2O retention (13, 14). It
has also been hypothesized that elevated levels of ROS within the hypothalamus may
alter sympathetic outflow and baroreceptor reflex, leading to increase in blood pressure
(32).

2.5 Measuring Oxidative Stress
ROS are reactive and unstable byproducts of oxygen metabolism (25). As such,
they are difficult to quantify. Accordingly, researchers have focused their attention on
oxidative status, which is used to characterize the relative state of oxidative load by
measuring oxidative damage to biological molecules (38). The accepted method of
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measuring oxidative status is via non‐enzymatically formed biomarkers of oxidative
damage (39). It is important to note that biomarkers of oxidative status capture the
extent of damage caused by ROS, not ROS itself. However, the amount of oxidative
damage is assumed to be proportional to the systemic levels of ROS that are not
captured by the antioxidant defense, thus presenting a balance between generation and
elimination of ROS at a systemic level (38). However, because ROS are ubiquitous and
play many functional roles in aerobic organisms, it remains unknown which levels of
oxidative status are considered to signify harmful oxidative stress as opposed to
physiologically normal levels.

2.6 F2‐Isoprostanes
F2‐isoprostanes are a group of bioactive compounds formed by the free radical‐
mediated peroxidation of archidonic acid, a lipid found within cellular membranes (40).
Extensive research has shown that F2‐isoprostanes are valid and reliable markers of
oxidative status in animals and humans (38). F2‐isoprostanes present biomarkers
suitable for epidemiological research because these molecules are chemically stable and
display high inter‐individual and low intra‐individual variation (41). Importantly, their
generation is not influenced by diet (42, 43). F2‐isoprostanes can be quantified in bodily
fluids using non‐invasive methods and they have been used in both clinical and
epidemiological studies. Because F2‐isoprostanes present an indices of the overall
oxidative status, they may be a valuable tool in predicting pathological cardiovascular
states and elucidating physiological processes involved with the development of adverse
cardiovascular functioning, such as hypertension (44, 45).
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2.7 Oxidative Status and Hypertension
There is a growing body of epidemiological inquiry applying F2‐isoprostane
quantification to hypertension research. Some of these studies have reported
significant increases in F2‐isoprostanes and other lipid peroxidation by‐products among
hypertensive cases compared to normotensive controls (46‐49). Researchers have also
observed elevated levels of hydrogen peroxide and superoxide radicals and decreased
concentrations of antioxidants including superoxide dismutase and alpha‐tocopherol
among hypertensive cases (50, 51). In contrast, other studies have yielded no significant
associations between F2‐isoprostanes and hypertension status (52, 53). Importantly, all
of the previously published studies are cross sectional, thus temporal relationships
between the exposure and outcome cannot be delineated.
Taking into account strong biological plausibility of ROS involvement with
dysfunction in various tissues that regulate blood pressure, and lack of information
about prospective associations between F2‐isoprostanes and incident hypertension, this
study examined whether a prospective relationship exists between F2‐isoprostanes and
hypertension incidence.

9

Chapter 3
Methods
3.1 Data Source
This analysis utilized existing data from the Insulin Resistance Atherosclerosis
Study (IRAS). IRAS is a prospective epidemiological study designed to assess the
relationships between insulin resistance, type‐two diabetes, cardiovascular disease, and
other risk factors among a multi‐centered sample of non‐Hispanic white, Hispanic, and
African American individuals (54). A total of 1625 men and women aged 40‐69 at
baseline were recruited between October 1992 and April 1994 from four clinical centers
located in San Antonio, Tx; San Luis Valley, Co; Oakland, CA and Los Angeles, CA. In
addition to racial/ethnic and geographic diversity, the IRAS study aimed to recruit
participants who were metabolically diverse. The sampling methodology ensured
adequate representation of groups with normal and impaired glucose tolerance in
addition to type‐two diabetes.

3.2 Case Ascertainment
Each participant’s hypertensive status was evaluated at baseline and follow‐up
examinations. Using a standard mercury column sphygmomanometer, resting blood
pressure was measured on three separate occasions during each examination. The
average of the 2nd and 3rd measurements were used in determining hypertensive status.
Hypertension was defined as a systolic blood pressure ≥140 mm Hg and/or diastolic
blood pressure ≥ 90 mm Hg, and/or a current regimen of antihypertensive medications.
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3.3 Covariates
The participants were followed for approximately five years. Baseline and
follow‐up examinations were each conducted during two visits, separated by one week.
Before each visit, participants were requested to fast for 12 hours and abstain from
alcohol, smoking, and heavy exercise. All participants completed an extensive
examination that assessed many demographic, lifestyle, and anthropometric variables.
Age, gender, race/ethnicity, and smoking status were self‐reported and captured using
validated questionnaires. The analytical cohort included non‐diabetic participants at
baseline as determined by the oral glucose tolerance test. Impaired glucose tolerance
was assessed at baseline and follow‐up visits using a 75g oral glucose tolerance test.
Body mass index (BMI) was calculated as weight in kilograms divided by height in square
meters for each participant and represented overall adiposity.

3.4 Assessment of Main Exposure: Urinary F2‐Isoprostanes
During the baseline examination, morning spot urine samples were taken from
all participants and stored at ‐70o C. F2‐isoprostanes were quantified using liquid
chromatography/tandem mass spectrometry and adjusted for urinary creatinine
concentration. A total of four isomers [(iPF(2𝛼)‐III), (2,3‐dinor‐iPF(2𝛼)‐III), (iPF(2𝛼)‐IV),
(8,12‐iso‐iPF(2𝛼)‐IV)] were evaluated. After excluding individuals with baseline diabetes
and those with missing values on any variable from either baseline or follow‐up
examinations due to loss of follow‐up or technical complications, we included 844 non‐
diabetic participants in the current analysis.
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Chapter 4
Statistical Analysis
4.1 Main Exposure
In the presented analysis, the four F2‐isoprostane variants [(iPF(2𝛼)‐III), (2,3‐
dinor‐iPF(2𝛼)‐III), (iPF(2𝛼)‐IV), (8,12‐iso‐iPF(2𝛼)‐IV)] will be referred to as F2‐isoP1, F2‐
isoP2, F2‐isoP3, F2‐isoP4, respectively. Additionally, an F2‐isoprostane index (F2‐isoP
index) variable was created by calculating the standardized mean of the four isomers.
Lastly, principle components analysis, which is a variable reduction technique, was
conducted on the original F2‐isoprostane isomers in order to identify a smaller set of
factors that would explain a majority of the shared variance between all four isomers,
yet exhibit no correlation/co‐linearity when included together in a linear model of
hypertension. Principle component analysis resulted in identification of two unique
factors that collectively explained approximately 80 % of the shared variance between
F2‐isoP1, F2‐isoP2, F2‐isoP3, and F2‐isoP4. These factors were included together in the
logistic regression model of hypertension discussed later in the study.

4.2 Crude Associations: Hypertension Status and Covariates
The examination of unadjusted associations between prevalent hypertension
and categorical variables was carried out using 𝑋 ! tests. Similarly, the crude
associations between categorical study characteristics and incident hypertensive cases
were assessed using 𝑋 ! tests. In addition, the Wilcoxon‐rank sum test was used to
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assess whether BMI and F2‐isoP levels differed between those with and without
prevalent and incident hypertension.

4.3 Crude Associations: F2 ‐isoprostanes and Covariates
In order to compare F2‐isoP levels among the strata of a categorical variable, this
study utilized the Wilcoxon‐rank sum and Kruskal‐Wallis test. The Spearman correlation
coefficient was used to examine the associations between F2‐isoPs and continuous
variables.

4.4 Adjusted Associations: Hypertension Status and F2‐isoprostanes
This study included a cross‐sectional and a prospective analysis to assess the
relationship between hypertension status and the main exposure, urinary F2‐isoP.
Logistic regression modeling was performed to assess adjusted cross‐sectional and
prospective associations between hypertension status and F2‐isoP. Fully adjusted and
minimally adjusted models were included in both analyses. The minimally adjusted
model included age (years), sex, ethnicity (African‐American/non‐Hispanic white/
Hispanic), clinic location (four strata), and BMI (kg/m2). The fully adjusted model
included two additional variables: smoking status (never/former/current) and IGT status
(normal/ impaired glucose tolerance). The adjusted odds ratios for continuous
covariates and F2‐isoP predictors were scaled by their respective standard deviations.
With the exception of the two F2‐isoP factors created by principle component analysis,
all of the original F2‐isoP variables and the standardized index were included separately
in each logistic regression model. This was done to prevent statistical issues that can

13
arise from co‐linearity between predictors. The statistical analysis was performed using
the SAS software package (version 9.3; SAS Institute, Cary N.C.). All statistical results
were assessed at the p‐value <0.05.

Chapter 5
Results
5.1 Crude Associations: Hypertension Status and Covariates
At baseline (Table 1), 30.6% of the study population was classified as
hypertensive. The normotensive group was approximately five years younger than their
hypertensive counterpart (p<0.001). There also existed a significant difference in the
proportion of hypertensive cases with respect to race/ethnicity (p<0.001). Among
African‐Americans, 40.6% were classified as hypertensive baseline. In contrast, only
26% of whites and 28% of non‐white Hispanics were hypertensive at baseline. Smoking
was not associated with prevalent hypertension in this study population. There was a
significant difference in the proportion of hypertensive cases with respect to IGT‐status
(p<0.0001). Among the participants with normal glucose tolerance, only 26% were
hypertensive, while 41% of individuals with impaired glucose tolerance were
hypertensive. Hypertensive individuals on average had greater BMI as compared to
normotensive (p=0.0001). The normotensive and hypertensive groups differed by
varying degrees of significance with respect to the four F2‐isoP concentrations.
Interestingly, F2‐isoP1 (p=0.04) and F2‐IsoP3 (p=0.001) were lower among individuals
with a normotensive status at baseline.
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Table 1. Study characteristics and hypertension status
Cross Sectional

Characteristics
Age
Gender (%)
Male
Female
Ethnicity (%)
White
African American
Non‐white Hispanic
IGT Status (%)
Normal
IGT
Smoking Status (%)
Never
Past
Current

Normotensive
At Baseline
n= 586
53 ± 8.2

Hypertensive
At Baseline
n= 258
58 ± 7.7

250 (42.7)
336 (57.3)

110 (42.6)
148 (57.4)

250 (42.7)
139 (23.7)
197 (33.6)

88 (34.1)
95 (36.8)
75 (29.1)

424 (72.4)
162 (27.7)

146 (56.6)
112 (43.4)

273 (46.6)
221 (37.7)
92 (15.7)

121 (46.9)
110 (42.6)
27 (10.5)

Prospective

p*
<0.001
0.9

Normotensive
At Follow‐up
n= 463
53 ± 8.1

Hypertensive
At Follow‐up
n= 123
54 ± 8.6

187 (40.4)
276 (59.6)

63 (51.2)
60 (48.8)

200 (43.2)
100 (21.6)
163 (35.2)

50 (40.7)
39 (31.7)
34 (27.6)

342 (73.9)
121 (26.1)

82 (66.7)
41 (33.3)

223 (48.2)
164 (35.4)
76 (16.4)

50 (40.7)
57 (46.3)
16 (13)

<0.001

p*
0.1
0.03

0.05

< 0.0001

0.1

0.1

0.08

BMI
27.6 ± 5.2
30.2 ± 6.1
0.0001
27.37 ± 5.07
28.58 ± 5.73
0.03
F2‐isoP1
0.25 ± 0.18
0.24 ± 0.2
0.04
0.25 ± 0.18
0.24 ± 0.23
0.1
F2‐isoP2
4.29 ± 3.07
4.47 ± 2.84
0.4
4.39 ± 3.21
3.86 ± 2.46
0.02
F2‐isoP3
6.7 ± 4.14
6.01 ± 4.2
0.001
6.76 ± 4.06
6.48 ± 4.44
0.1
F2‐isoP4
4.17 ± 2.76
4.08 ± 3.11
0.2
4.19 ± 2.78
4.07 ± 2.66
0.6
F2‐isoP Index
0.01 ± 0.8
‐0.04 ± 0.86
0.07
0.03 ± 0.79
‐0.06 ± 0.84
0.09
*
Categorical variables were reported as n, (%) and assessed using Chi Square test
Continuous variables were reported as mean ± SD but assessed using Wilcoxon Rank Sum/ Kruskal Wallis
test

Among those who were classified as normotensive at baseline (n = 586), 21%
developed hypertension during the five‐year study period (Table 1). Unlike the cross‐
sectional analysis, there was no significant difference between incidence hypertension
cases and non‐cases with respect to age. However, the proportion of males who
developed hypertension (25.2%) was significantly greater (p=0.03) as compared to the
proportion of females developing hypertension (17.9%). With respect to race/ethnicity,
there was a marginally significant difference between the proportions of those who
developed hypertension (p=0.05). Similar to the cross sectional analysis, the African
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American stratum exhibited a greater proportion of individuals who developed
hypertension (28%) compared to white (20%) and non‐white Hispanic (17%) strata.
However, there was no significant difference between hypertension incidence with
respect to IGT‐status or smoking. Median baseline BMI among the cases was lower (p =
0.03) compared to their normotensive counterparts. Among the five F2‐isoP
measurements, only F2‐isoP2 (p=0.02) differed significantly between the normotensive
(4.39 ± 3.21 ng/mg creatinine) and hypertensive group (3.86 ± 2.46 ng/mg creatinine).

5.2 Crude Associations: F2‐isoprostanes and Covariates
To assess the association between characteristics of the study population and
oxidative damage, each stratum of a given categorical variable were compared with
respect to median F2‐isoP (Table 2). Females consistently displayed greater levels of all
five F2‐isoP (p ≤ 0.002). Among the race/ethnicity strata, Hispanics showed greater
levels of all five F2‐isoP measurements, while African‐Americans displayed the lowest
concentrations. Impaired glucose tolerance was not consistently associated with F2‐isoP
levels and showed a significant increase (p=0.03) in only F2‐isoP2. Additionally, there
were significant differences in F2‐isoP1 (p<0.0001), F2‐isoP3 (p=0.02), and the F2‐isoP
index (p<0.001) with respect to smoking status. While smokers displayed greater F2‐
isoP, past smokers typically displayed the lowest levels of F2‐isoP.
Significant inverse associations were observed between age and two F2‐isoP
measurements: F2‐isoP4 (p<0.001) and the F2‐isoP index (p=0.04). Finally, there was a
significant positive association between BMI and F2‐isoP2 (p<0.001), F2‐isoP4 (p< 0.004),
and the F2‐isoP index (p=0.007).
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Table 2. Associations between F2‐IsoPs (ng/mg creatinine) and study characteristics
F2‐IsoP2
F2‐IsoP3
[2,3‐dinor‐
[iPF(2𝜶)‐IV]
iPF(2𝜶)‐III]
Categorical demographic and baseline characteristics; mean (s.d.)
Gender
Male
0.19 (0.16)
3.19 (1.85)
5.01 (3.12)
F2‐IsoP1
[iPF(2𝜶)‐III]

Female

‐0.29 (0.62)

7.59 (4.49)

4.42 (3.12)

0.21 (0.88)

P<0.0001

P<0.001

P<0.001

P=0.002

P<0.001

Non‐
Hispanic
White

0.24 (0.17)

4.08 (2.29)

6.24 (3.74)

4.13 (2.65)

‐0.05 (0.69)

African
American

0.19 (0.15)

3.59 (2.06)

5.08 (2.98)

3.26 (2.03)

‐0.31 (0.56)

Hispanic

0.31 (0.24)

5.31 (4.04)

8.02 (4.99)

4.93 (3.47)

0.32 (1.02)

P<0.0001

P<0.0001

P<0.0001

P<0.0001

P<0.0001

Normal

0.25 (0.21)

4.19 (3.01)

6.42 (3.99)

4.09 (2.91)

‐0.02 (0.83)

IGT

0.24 (0.16)

4.64 (2.96)

6.65 (4.52)

4.24 (2.78)

0.03 (0.79)

P=0.55

P=0.03

P=0.94

P=0.28

P=0.34

Never

0.24 (0.18)

4.34 (2.69)

6.75 (4.36)

4.2 (2.83)

0.01 (0.79)

Past

0.23 (0.16)

4.17 (3.27)

6.08 (4.05)

3.94 (2.64)

‐0.09 (0.79)

Current

0.34 (0.27)

4.83 (3.18)

6.76 (3.76)

4.53 (3.51)

0.19 (0.96)

P<0.0001

P=0.05

p=0.02

P=0.15

P<0.001

p‐value
Smoking
Status

3.77 (2.44)

5.19 (3.39)

p‐value
IGT Status

F2‐IsoP
Index

0.29 (0.2)

p‐value
Ethnicity

F2‐IsoP4
[8,12‐iso‐
iPF(2𝜶)‐IV]

p‐value

a

a

a

a

Continuous anthropometric baseline characteristics. Spearman correlation coefficients (p‐value)
Age

‐0.01 (0.7)

‐0.03 (0.3)

‐0.03 (0.4)

‐0.19 (<0.001)

‐0.07 (0.04)

BMI

0.0 (0.9)

0.18 (<0.001)

0.04 (0.3)

0.1 (0.004)

0.09(0.007)

a

Wilcoxon rank sum/ Kruskal‐ Wallis test
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5.3 Adjusted Associations Hypertension Status and F2‐Isoprostanes
The minimally and fully adjusted odds of prevalent hypertension (Table 3) were
calculated using two sets of covariates as defined in the Methods section. Overall, there
was no consistent association between F2‐isoP and hypertension prevalence, as the OR
point estimates ranged from 0.81 to 1.05 in the reduced model and 0.82 to 1.05 in the
full model. However, a marginal inverse association was found between F2‐IsoP3 and
hypertension prevalence in the reduced (C.I. 95%=0.67,0.99) and the full model (C.I.
95%= 0.68,0.99).
Table 3. Multivariable logistic regression of baseline hypertension on F2‐isoprostanes
Baseline Hypertension (n=258)
F2‐isoprostanes
(ng/mg creatinine)

ORa (95%CI)

ORa (95% CI)

Model 1b

Model 2c

F2‐IsoP1 [iPF(2𝛼)‐III]

0.99 (0.83,1.19)

1.02 (0.85,1.23)

F2‐IsoP2 [2,3‐dinor‐iPF(2𝛼)‐III]

0.98 (0.83,1.16)

0.99 (0.83,1.17)

F2‐IsoP3 [iPF(2𝛼)‐IV]

0.81 (0.67,0.99)

0.82 (0.68,0.99)

F2‐IsoP4 [8,12‐iso‐iPF(2𝛼)‐IV]

1.05 (0.88,1.24)

1.05 (0.88,1.25)

F2‐isoP Index

0.94 (0.78,1.14)

0.96 (0.79,1.15)

Factor 1

0.95 (0.79, 1.16)

0.92 (0.77, 1.10)

Factor 2

1.01 (0.86, 1.18)

0.99 (0.84, 1.16)

CI, confidence interval; OR, odds ratio
a
Odds ratios scaled by respective standard deviation
b
Reduced model adjusted for the following variables: age, gender, race/ethnicity, clinic, BMI
c
Full model adjusted for the following variables: age, gender, race/ethnicity, clinic, smoking status, IGT
status, BMI
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In a similar manner, the associations between F2‐isoP and incident hypertension
were examined (Table 4). In both the fully and minimally adjusted models, none of F2‐
isoPs predicted a significant change in the odds of incident hypertension. These results
do not support the theory that increased oxidative status is causally related to
hypertension.
Table 4. Multivariable logistic regression of incident hypertension on F2‐isoprostanes
Hypertension at follow‐up (n=463)
F2‐isoprostanes
(ng/mg creatinine)

ORa (95%CI)

ORa (95% CI)

Model 1b

Model 2c

F2‐IsoP1 [iPF(2𝛼)‐III]

1.06 (0.85, 1.31)

1.08 (0.86,1.36)

F2‐IsoP2 [2,3‐dinor‐iPF(2𝛼)‐III]

0.84 (0.62, 1.13)

0.84 (0.62, 1.13)

F2‐IsoP3 [iPF(2𝛼)‐IV]

1.01 (0.80, 1.27)

1.0 (0.79,1.27)

F2‐IsoP4 [8,12‐iso‐iPF(2𝛼)‐IV]

1.04 (0.84, 1.29)

1.05 (0.85,1.31)

F2‐isoP Index

0.99 (0.78, 1.26)

1.0 (0.8, 1.3)

Factor 1

0.96 (0.74, 1.25)

0.88 (0.69, 1.12)

Factor 2

0.81 (0.63, 1.06)

0.77 (0.60, 1.01)

CI, confidence interval; OR, odds ratio
a
Odds ratios scaled by respective standard deviation
b
Reduced model adjusted for the following variables: age, gender, race/ethnicity, clinic, BMI
c
Full model adjusted for the following variables: age, gender, race/ethnicity, clinic, smoking status, IGT
status, BMI
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Chapter 6
Discussion
6.1 Primary Findings
Using the cross‐sectional and prospective designs, this analysis investigated the
association between urinary F2‐isoP and hypertension status in a large cohort with
demographic, anthropometric, and metabolic diversity. This study produced two main
findings. First, the analysis could not establish a significant relationship between
increased oxidative status and hypertension prevalence. After controlling for a minimal
set of potential confounders, the ORs associated with seven F2‐isoP measurements
ranged from 0.81 to 1.05. Similarly, the range of the fully adjusted ORs ranged from
0.82 to 1.05. These findings are consistent and in agreement with previously published
studies that found no evidence of increased F2‐IsoP levels among the prevalent
hypertensive cases (52, 53).
With respect to incident hypertension, to the best of our knowledge, this is the
first study to conduct a prospective study between F2‐isoP levels and hypertension. The
minimally and fully adjusted odds ratios ranged from 0.81 to 1.06 and from 0.77 to 1.08,
respectively, with none of the associations reaching statistical significance. These
results suggest that increased oxidative status, as measured by F2‐isoP, is not causally
related to hypertension pathogenesis. Other lines of evidence support this reasoning.
First, it has been shown that ROS generation occurs because of endothelial dysfunction
(55). One study also showed that men treated with anti‐hypertensive medication
exhibited lower concentrations of F2‐isoP compared to untreated controls (53).
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Additionally, large clinical trials of antioxidants have shown inconsistent results in
reducing blood pressure (56).
Interestingly, two sets of crude associations also contradict the original
hypothesis that increased oxidative status is casually associated with hypertension.
African‐Americans exhibited the lowest baseline concentrations of F2‐isoP, yet also
exhibited the greatest proportion of hypertensive cases at baseline and follow‐up. If the
original hypothesis were true, we would expect to see a direct association between the
primary exposure and outcome.

6.2 Secondary Findings
Importantly, several expected associations between known risk factors and
hypertension have been found. For example, this study found that age differed
significantly between baseline normotensives and their hypertensive counterparts.
Accordingly, age is a known risk factor for hypertension and cardiovascular disease (12).
Interestingly, this association was not present in the crude prospective association. One
reason for this may be a lack of age variability in the sub‐group who were normotensive
at baseline. While previous studies found a positive association between F2‐isoP and
age (5), this analysis found significant inverse associations between age and two of the
four F2‐isoP measurements. One possible explanation for this association is that
oxidative metabolism capacity declines with age. Additionally, this study found
expected crude associations between hypertension status and race/ethnicity (57), IGT
status (18), and BMI (58). Although positive associations between hypertension and F2‐
isoP concentrations have been found in previous cross‐sectional studies (46, 47, 49, 59),
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the cross‐sectional associations were marginally significant in this study, suggesting a
potential protective trait of increased oxidative status. Indeed, some researchers
theorize that an increased concentration of F2‐isoPs reflect a favorable trait and infers a
reduced risk of weight gain and development of diabetes (60).
The unadjusted associations between baseline study characteristics and F2‐isoP
species produced several expected findings. F2‐isoP levels differed significantly between
males and females. However, this may be explained by the adjustments made for
urinary diluteness during quantification of urinary biomarkers. Specifically, corrections
for creatinine levels were made to all F2‐isoP concentrations. Since creatinine levels are
influenced by the lean muscle mass, these adjustments can increase observed
concentrations among women, because women on average have lower muscle as
compared to men (60). This study also reproduced associations between F2‐isoP and
smoking status (41) and BMI (58).

6.3 Conclusion
Despite advances in prevention and treatment, hypertension is still one of the
most common conditions in the world, and for a majority of cases the causal
mechanisms remain to be fully understood. Many experimental studies have implicated
oxidative stress in the pathogenesis of hypertension. However, epidemiological studies
have not provided consistent results. Additionally, most of the epidemiological studies
are cross sectional and thus, cannot establish temporal relationships between the
exposure and outcome. The main objective of this study was to investigate the
prospective relationship between oxidative status, as measured by F2‐isoP, and
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hypertension incidence. The results of this study do not support the hypothesis that
elevated oxidative status can inform hypertension risk. While this study implemented
the prospective design to establish a temporal relationship between oxidative stress
status and hypertension there were several inherent limitations. These include
dichotomization of hypertension and a lack of repeated blood pressure and F2‐isoP
observations during the five‐year study period. Additionally, oxidative status must be
assessed indirectly through oxidative damage. Since there are multiple biological
pathways involved with hypertension, additional measures of oxidative damage may
provide a more comprehensive assessment of oxidative stress status.
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